adenosine monophosphate has been researched along with Coronary Thrombosis in 30 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (13.33) | 29.6817 |
| 2010's | 23 (76.67) | 24.3611 |
| 2020's | 3 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ben-Dor, I; Bernardo, NL; Bhogal, S; Devineni, A; Garcia-Garcia, HM; Hashim, HD; Kallur, A; Merdler, I; Rogers, T; Satler, LF; Waksman, R; Wermers, JP | 1 |
| Garcia-Garcia, HM; Jeremias, A; Melaku, GD; Sacher, H; Shlofmitz, E; Shlofmitz, R; Thomas, SV; Torguson, R; Waksman, R | 1 |
| Buono, A; De Blasio, G; Ielasi, A; Loffi, M; Tespili, M | 1 |
| Droppa, M; Geisler, T | 1 |
| Amin, AP; Bhatt, DL; Fan, W; Généreux, P; Gibson, CM; Harrington, RA; Kirtane, AJ; Pinto, DS; Stone, GW; Tamez, H; White, HD; Yeh, RW | 1 |
| Bowman, S; Gass, J; Weeks, P | 1 |
| Banerjee, S; Baskar, A; Chauhan, S; Cui, Z; Dargham, BB; Sum-Ping, J; Tejani, I; Weideman, RA | 1 |
| Erlinge, D; Grimfjärd, P; James, S; Lagerqvist, B; Varenhorst, C | 1 |
| Beyene, S; Brathwaite, E; Buchanan, K; Dan, K; Dheendsa, A; Gajanana, D; Garcia-Garcia, HM; Hideo-Kajita, A; Iantorno, M; Kolm, P; Meirovich, Y; Melaku, G; Ozaki, Y; Rogers, T; Torguson, R; Waksman, R | 1 |
| Abtan, J; Bhatt, DL; Deliargyris, EN; Ducrocq, G; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Bhatt, DL; Gibson, CM; Hamm, CW; Harrington, RA; Leonardi, S; Lopes, RD; Mahaffey, KW; Mangum, S; Olivier, CB; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilson, MD | 1 |
| Storey, RF | 1 |
| Limbruno, U; Musumeci, G | 1 |
| Price, MJ; Walsh, JA | 1 |
| Sabouret, P; Taiel-Sartral, M | 1 |
| Dobesh, PP; Oestreich, JH | 1 |
| Bhatt, DL; Cortese, B; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Liu, T; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD; Wilensky, M | 1 |
| Traynor, K | 1 |
| Keating, GM | 1 |
| Bhatt, DL; Blankenship, JC; Deliargyris, EN; Généreux, P; Gibson, CM; Gutierrez, JA; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Frelinger, AL; Gremmel, T; Michelson, AD; Przyklenk, K; Undyala, VV; Wider, J; Wright, GE; Yanachkov, IB; Yanachkova, MI | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; Vaduganathan, M; White, HD | 1 |
| Abnousi, F; Abtan, J; Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Steg, PG; Stone, GW; White, HD | 1 |
| Bhatt, DL; Deliargyris, EN; Gibson, CM; Hamm, CW; Harrington, RA; Mahaffey, KW; Prats, J; Price, MJ; Sawlani, NN; Steg, PG; Stone, GW; White, HD | 1 |
| Norgard, NB | 1 |
| Arneja, J; Bhatt, DL; Chew, DP; Cura, F; Gibson, CM; Goodman, SG; Harrington, RA; Jafar, MZ; Kleiman, NS; Lincoff, AM; Mahaffey, KW; Manoukian, SV; Manukov, I; McNulty, S; Montalescot, G; Pollack, CV; Skerjanec, S; Stone, GW; Tousek, F; White, HD; Widimsky, P | 1 |
| Lee, KL | 1 |
| Frey, N; Ivandic, B | 1 |
| Cudd, LA; Fugate, SE | 1 |
| Cattaneo, M | 1 |
8 review(s) available for adenosine monophosphate and Coronary Thrombosis
| Article | Year |
|---|---|
What is the Role of Cangrelor in Patients Undergoing PCI?
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Administration, Intravenous; Coronary Artery Disease; Coronary Thrombosis; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Treatment Outcome | 2018 |
Cangrelor for treatment of arterial thrombosis.
Topics: Adenosine Monophosphate; Coronary Artery Disease; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Stents | 2014 |
New antiplatelet agents in the treatment of acute coronary syndromes.
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Clinical Trials as Topic; Clopidogrel; Combined Modality Therapy; Coronary Artery Bypass; Coronary Thrombosis; Diabetes Complications; Hemorrhage; Humans; Multicenter Studies as Topic; Piperazines; Platelet Aggregation Inhibitors; Practice Guidelines as Topic; Prasugrel Hydrochloride; Precision Medicine; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2Y12; Renal Insufficiency; Thiophenes; Ticagrelor; Ticlopidine; Treatment Outcome | 2014 |
Cangrelor: A Review in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Blood Platelets; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Risk Factors; Treatment Outcome | 2015 |
Cangrelor: a novel P2Y12 receptor antagonist.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Animals; Clinical Trials as Topic; Coronary Thrombosis; Drug Evaluation, Preclinical; Humans; Molecular Structure; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists; Receptors, Purinergic P2Y12 | 2009 |
[New approaches and indications for the analysis of platelet function in cardiology].
Topics: Acute Coronary Syndrome; Adenosine; Adenosine Monophosphate; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Interactions; Hemorrhage; Humans; Piperazines; Platelet Activation; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prasugrel Hydrochloride; Purinergic P2Y Receptor Antagonists; Thiophenes; Ticagrelor; Ticlopidine | 2011 |
Cangrelor for treatment of coronary thrombosis.
Topics: Adenosine Monophosphate; Animals; Clinical Trials as Topic; Coronary Thrombosis; Drug Interactions; Humans; Platelet Aggregation Inhibitors; Purinergic P2 Receptor Antagonists | 2006 |
Platelet P2 receptors: old and new targets for antithrombotic drugs.
Topics: Adenosine; Adenosine Monophosphate; Angina, Unstable; Animals; Blood Platelets; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Interactions; Fibrinolytic Agents; Humans; Myocardial Infarction; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; Purinergic P2 Receptor Antagonists; Randomized Controlled Trials as Topic; Receptors, Purinergic P2; Receptors, Purinergic P2X; Syndrome; Thiophenes; Ticagrelor; Ticlopidine | 2007 |
6 trial(s) available for adenosine monophosphate and Coronary Thrombosis
| Article | Year |
|---|---|
Cost implications of intraprocedural thrombotic events and bleeding in percutaneous coronary intervention: Results from the CHAMPION PHOENIX ECONOMICS Study.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Cost-Benefit Analysis; Double-Blind Method; Drug Costs; Female; Hemorrhage; Hospital Costs; Hospital Mortality; Humans; Length of Stay; Male; Middle Aged; Models, Economic; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Risk Factors; Time Factors; Treatment Outcome; United States | 2018 |
Outcomes with cangrelor versus clopidogrel on a background of bivalirudin: insights from the CHAMPION PHOENIX (A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention [PCI]).
Topics: Adenosine Monophosphate; Aged; Anticoagulants; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Hirudins; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Peptide Fragments; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Recombinant Proteins; Risk Factors; Stents; Ticlopidine; Time Factors; Treatment Outcome | 2015 |
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX.
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Femoral Artery; Graft Occlusion, Vascular; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Radial Artery; Stents; Ticlopidine; Treatment Outcome | 2016 |
Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial.
Topics: Adenosine Monophosphate; Aged; Brazil; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Europe; Female; Hemorrhage; Humans; Intention to Treat Analysis; Kaplan-Meier Estimate; Logistic Models; Male; Middle Aged; New Zealand; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Risk Factors; Thailand; Ticlopidine; Time Factors; Treatment Outcome; United States | 2016 |
Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: The CHAMPION PHOENIX Trial.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angina, Stable; Chi-Square Distribution; Clopidogrel; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Risk Factors; Ticlopidine; Time Factors; Treatment Outcome | 2016 |
Intravenous platelet blockade with cangrelor during PCI.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Stents; Treatment Outcome | 2009 |
16 other study(ies) available for adenosine monophosphate and Coronary Thrombosis
| Article | Year |
|---|---|
Aspiration Thrombectomy With and Without Cangrelor During Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Coronary Thrombosis; Humans; Percutaneous Coronary Intervention; Thrombectomy; Treatment Outcome | 2023 |
Impact of Cangrelor on Coronary Thrombus: Optical Coherence Tomography Assessment.
Topics: Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Coronary Angiography; Coronary Thrombosis; Drug-Eluting Stents; Humans; Male; Middle Aged; Non-ST Elevated Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Tomography, Optical Coherence; Treatment Outcome | 2020 |
Intracoronary cangrelor administration-assisted primary percutaneous coronary intervention in a patient with essential thrombocythemia and recurrent ST-segment elevation myocardial infarction.
Topics: Adenosine Monophosphate; Adult; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug-Eluting Stents; Humans; Hydroxyurea; Infusions, Intravenous; Male; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Recurrence; ST Elevation Myocardial Infarction; Thrombocythemia, Essential; Treatment Outcome | 2020 |
Antiplatelet Therapy Bridging With Cangrelor in Patients With Coronary Stents: A Case Series.
Topics: Adenosine Monophosphate; Administration, Oral; Aged; Aged, 80 and over; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Substitution; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Platelet Function Tests; Postoperative Care; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Stents; Treatment Outcome | 2019 |
Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Administration, Intravenous; Aged; Aspirin; Cardiac Surgical Procedures; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Drug Administration Schedule; Drug Substitution; Drug Therapy, Combination; Drug-Eluting Stents; Eptifibatide; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Perioperative Care; Platelet Aggregation Inhibitors; Retrospective Studies; Risk Factors; Time Factors; Tirofiban; Treatment Outcome | 2019 |
Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR).
Topics: Adenosine Monophosphate; Aged; Coronary Thrombosis; Drug Utilization; Female; Hemorrhage; Humans; Male; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Practice Patterns, Physicians'; Purinergic P2Y Receptor Antagonists; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Sweden; Time Factors; Treatment Outcome | 2019 |
Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Coronary Angiography; Coronary Thrombosis; Female; Follow-Up Studies; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Purinergic P2Y Receptor Antagonists; Retrospective Studies; Treatment Outcome | 2019 |
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y
Topics: Adenosine Monophosphate; Aged; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Female; Hemorrhage; Humans; Male; Middle Aged; Myocardial Infarction; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Factors; Stents; Time Factors; Treatment Outcome | 2019 |
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Coronary Artery Disease; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Research Design; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome | 2019 |
Antiplatelet therapy. Cangrelor succeeds, at last, in PCI.
Topics: Adenosine Monophosphate; Administration, Intravenous; Administration, Oral; Blood Platelets; Clopidogrel; Coronary Thrombosis; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Receptors, Purinergic P2Y12; Ticlopidine; Treatment Outcome | 2013 |
[The CHAMPION PHOENIX study].
Topics: Adenosine Monophosphate; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Coronary Thrombosis; Double-Blind Method; Hemorrhage; Humans; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Stents; Ticlopidine | 2013 |
Cangrelor for treatment during percutaneous coronary intervention.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aspirin; Clinical Trials as Topic; Coronary Thrombosis; Drug Interactions; Drug Therapy, Combination; Humans; Myocardial Infarction; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Postoperative Complications; Purinergic P2Y Receptor Antagonists; Stents | 2014 |
Cangrelor approved for use during coronary angioplasty.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Coronary Thrombosis; Drug Approval; Humans; Infusions, Intravenous; Intraoperative Care; Platelet Aggregation Inhibitors; United States; United States Food and Drug Administration | 2015 |
Synergistic Inhibition of Both P2Y1 and P2Y12 Adenosine Diphosphate Receptors As Novel Approach to Rapidly Attenuate Platelet-Mediated Thrombosis.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Adult; Animals; Aspirin; Blood Coagulation; Blood Platelets; Coronary Thrombosis; Dinucleoside Phosphates; Disease Models, Animal; Dogs; Dose-Response Relationship, Drug; Female; Fibrinolytic Agents; Humans; Male; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Purinergic P2Y Receptor Antagonists; Rats, Sprague-Dawley; Receptors, Purinergic P2Y1; Receptors, Purinergic P2Y12; Time Factors; Young Adult | 2016 |
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention.
Topics: Adenosine Monophosphate; Aged; Brain Ischemia; Chi-Square Distribution; Clopidogrel; Coronary Artery Disease; Coronary Thrombosis; Female; Hemorrhage; Humans; Ischemic Attack, Transient; Logistic Models; Male; Middle Aged; Myocardial Infarction; Odds Ratio; Percutaneous Coronary Intervention; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Ticlopidine; Time Factors; Treatment Outcome | 2017 |
Testing a new approach for rapid and reversible platelet inhibition during percutaneous coronary intervention among patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Aged; Angioplasty, Balloon, Coronary; Combined Modality Therapy; Coronary Thrombosis; Double-Blind Method; Female; Hemorrhage; Humans; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Retreatment; Stents; Treatment Outcome | 2010 |